A
Aparajita Chowdhury
Researcher at University of Nebraska Medical Center
Publications - 7
Citations - 237
Aparajita Chowdhury is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Centrosome & Cell cycle checkpoint. The author has an hindex of 5, co-authored 7 publications receiving 212 citations.
Papers
More filters
Journal ArticleDOI
Inorganic arsenic: A non-genotoxic carcinogen.
TL;DR: The data strongly supports a non-linear dose response for the effects of inorganic arsenic, and in various in vitro and in vivo models and in human epidemiology studies there appears to be a threshold for biological responses, including cancer.
Journal ArticleDOI
KIBRA regulates aurora kinase activity and is required for precise chromosome alignment during mitosis.
Lin Zhang,Jyoti Iyer,Aparajita Chowdhury,Ming Ji,Ling Xiao,Shuping Yang,Yuanhong Chen,Ming Ying Tsai,Jixin Dong +8 more
TL;DR: It is proposed that the KIBRA-Aurora-Lats2 protein complexes form a novel axis that regulates precise mitosis, which is consistent with playing a role in mitosis.
Journal ArticleDOI
Identification of a Novel TGFβ/PKA Signaling Transduceome in Mediating Control of Cell Survival and Metastasis in Colon Cancer
Sanjib Chowdhury,Gillian M. Howell,Ashwani Rajput,Carol A. Teggart,Lisa E. Brattain,Hannah R. Weber,Aparajita Chowdhury,Michael G. Brattain +7 more
TL;DR: This work demonstrates for the first time that TGFβ receptor reconstitution leads to decreased metastatic colonization and indicates the clinical potential for developing anti-metastasis therapy based on inhibition of this very important aberrant cell survival mechanism by the multifaceted TGF β/PKA transduceome induced pathway.
Journal ArticleDOI
Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor β (TGFβ) Receptor II Leading to Cancer Cell Death
Sanjib Chowdhury,Gillian M. Howell,Carol A. Teggart,Aparajita Chowdhury,Dawn M. Bowers,Michael G. Brattain +5 more
TL;DR: Patients exhibiting high survivin expression with epigenetically silenced TGFβRII with concomitant survivin repression may represent a significant mechanism in the anticancer effects of this drug, and might potentially benefit from the use of this histone deacetylase inhibitor.
Journal ArticleDOI
A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
TL;DR: It is demonstrated that treatment with MK-8745 leads to cell cycle arrest at the G2/M phase with accumulation of tetraploid nuclei followed by cell death in non-Hodgkin lymphoma (NHL) cell lines, and results indicate that TPX2 may serve as a biomarker for identifying subpopulations of patients sensitive to Aurora-A inhibitor treatment.